Health Care & Life Sciences » Pharmaceuticals | Amicus Therapeutics Inc.

Amicus Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
82
152
214
330
359
504
Total Accounts Receivable
1
-
-
1
9
22
Inventories
-
-
-
3
5
8
Other Current Assets
6
3
3
5
19
17
Total Current Assets
88
155
217
340
392
551
Net Property, Plant & Equipment
4
3
6
10
9
11
Total Investments and Advances
-
17
-
-
-
-
Intangible Assets
35
35
684
684
221
221
Other Assets
1
1
1
2
5
7
Total Assets
128
210
908
1,037
627
790
ST Debt & Current Portion LT Debt
-
-
-
4
-
Accounts Payable
2
6
16
13
8
Other Current Liabilities
8
10
57
98
62
Total Current Liabilities
10
20
74
111
70
Long-Term Debt
14
11
42
154
164
Provision for Risks & Charges
-
11
233
214
-
Deferred Taxes
9
9
176
174
6
Other Liabilities
48
37
36
24
34
Total Liabilities
82
88
561
677
274
Common Equity (Total)
46
122
348
360
353
Total Shareholders' Equity
46
122
348
360
353
Total Equity
46
122
348
360
353
Liabilities & Shareholders' Equity
128
210
908
1,037
627

About Amicus Therapeutics

View Profile
Address
1 Cedar Brook Drive
Cranbury New Jersey 08512
United States
Employees -
Website http://www.amicusrx.com
Updated 07/08/2019
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.